IO Biotech’s Promising Phase 3 Cancer Vaccine Trial Advances
Company Announcements

IO Biotech’s Promising Phase 3 Cancer Vaccine Trial Advances

The latest announcement is out from IO Biotech (IOBT).

On August 30, 2024, the Company revealed positive news from its Phase 3 trial of the cancer vaccine IO102-IO103 used with KEYTRUDA® for treating advanced melanoma, with an Independent Data Monitoring Committee endorsing the trial’s continuation. This endorsement, based on favorable safety and efficacy data, signals steady progress towards the primary endpoint expected in early 2025, generating optimism among investors and stakeholders in the pharmaceutical sector.

For an in-depth examination of IOBT stock, go to TipRanks’ Stock Analysis page.

Related Articles
TheFlyIO Biotech reports data on IO102-IO103 vaccine in combination with KEYTRUDA
TheFlyIO Biotech price target raised to $6 from $4 at Morgan Stanley
TheFlyIO Biotech announces results from Phase 2 trial of IO102-IO103
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App